The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

The eye-care company Alcon Research has entered into licensing and purchase option agreements with Potentia Pharmaceuticals to develop Potentia's leading drug candidate — a complement pathway ...

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and ...

Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...

The complement cascade is a biochemical process in the blood that helps or 'complements' cells of the immune system to eliminate invading pathogens. When activated by one of three pathways ...

A total of 120 clinical investigative sites across 30 countries have been chosen for clinical trial participation in the zaltenibart Phase 3 program in PNH, a good number of which have already ...